BioMed Research International

BioMed Research International / 2015 / Article
Special Issue

Phytochemicals in Cancer Prevention and Therapy

View this Special Issue

Research Article | Open Access

Volume 2015 |Article ID 847457 |

Rosa Moo-Puc, Edgar Caamal-Fuentes, Sergio R. Peraza-Sánchez, Anna Slusarz, Glenn Jackson, Sara K. Drenkhahn, Dennis B. Lubahn, "Antiproliferative and Antiestrogenic Activities of Bonediol an Alkyl Catechol from Bonellia macrocarpa", BioMed Research International, vol. 2015, Article ID 847457, 6 pages, 2015.

Antiproliferative and Antiestrogenic Activities of Bonediol an Alkyl Catechol from Bonellia macrocarpa

Academic Editor: Kanjoormana A. Manu
Received10 Jul 2015
Revised24 Sep 2015
Accepted30 Sep 2015
Published18 Oct 2015


The purpose of this study was to investigate antiproliferative activity of bonediol, an alkyl catechol isolated from the Mayan medicinal plant Bonellia macrocarpa. Bonediol was assessed for growth inhibition of androgen-sensitive (LNCaP), androgen-insensitive (PC-3), and metastatic androgen-insensitive (PC-3M) human prostate tumor cells; toxicity on normal cell line (HEK 293) was also evaluated. Hedgehog pathway was evaluated and competitive 3H-estradiol ligand binding assay was performed. Additionally, antioxidant activity on Nrf2-ARE pathway was evaluated. Bonediol induced a growth inhibition on prostate cancer cell lines (IC50 from 8.5 to 20.6 µM). Interestingly, bonediol binds to both estrogen receptors (ERα (2.5 µM) and ERβ (2.1 µM)) and displaces the native ligand E2 (17β-estradiol). No significant activity was found in the Hedgehog pathway. Additionally, activity of bonediol on Nrf2-ARE pathway suggested that bonediol could induce oxidative stress and activation of detoxification enzymes at 1 µM (3.8-fold). We propose that the compound bonediol may serve as a potential chemopreventive treatment with therapeutic potential against prostate cancer.

1. Introduction

Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males. Approximately, one man in five will be diagnosed with prostate cancer during his lifetime, and 1 man in 33 will die of this disease [1]. Treatment for this disease may include radiation therapy and androgen suppression; surgery and/or chemotherapy are often used. However, adverse effects have been described, decreasing the quality of life of patients [2]. Furthermore, in 15% of the patients, the cancer recurs within a few years as an advanced “hormone-refractory” and often metastatic disease. For these patients, there are few treatment options available [3], and the 5-year survival rate decreases to 28% [4].

Chemotherapy is a good option for the treatment of hormone-independent and hormone-dependent prostate cancer; however, few therapies in clinical phase of development are available [5]. In addition, some cancers have proven to be resistant to chemotherapy drugs [6]. Therefore, identification of new drugs for prostate cancer treatment has significant clinical implications.

Currently one of the signaling pathways that has been of great interest because of its importance in the development and progression of prostate cancer is the sonic Hedgehog (Shh) signaling pathway. The Shh pathway involves the autocleavage of full length Shh into an active 20 kD N-terminal fragment (ShhN), which binds to its 12-pass transmembrane receptor, Patched (Ptc1), reversing (relieving) its inhibitory effect on Smoothened (Smo). In prostate cancer, Shh pathway can produce malignant transformation of primitive prostate epithelial progenitor cells; this may be initiated by trapping of a normal stem cell in a Shh-dependent state of continuous renewal, which promotes tumor growth [710].

The estrogen and Hedgehog signaling pathways are crucial for physiological proliferation, differentiation, and development of the mammary and prostate glands [11, 12]. It has also been found that activation of both Shh and ERα can lead to the growth of cancerous tumors (insert references here that show Shh and ERa in breast and prostate cancer). Moreover studies suggest that ERα regulates the Shh pathway and promotes cancer development [1317]. Recently a study using in vitro and in vivo models suggested estrogen, mediated through ERα and ERβ, could induce carcinogenesis and various types of toxicity in a normal prostate [18]. Investigations searching for new compounds that can inhibit the Hedgehog pathway and regulate the ERs to treat or prevent prostate cancer could have significant implications [19, 20].

A direct relationship between an increase in reactive oxygen species (ROS) and the induction of the Shh pathway has also been documented. This induction promotes the expression of the antiapoptotic gene Bcl-2 and inhibits the expression of the proapoptotic gene Bax [21]. In addition, Paschos et al. [22] suggest that androgens and estrogen play an important role in the generation of reactive oxygen species leading to the progression of prostate cancer and that the antioxidant activity of certain small molecules may prevent the progression of prostate cancer. NF-E2 Related Factor 2 (Nfr2) is an important transcription factor responsible for stimulating the transcription of genes in response to oxidative or electrophilic stress [23]. This process involves the binding of Nrf2 with Maf protein in the nucleus to form a heterodimer, subsequently interacting with antioxidant responsive element (ARE) to activate gene transcription [24]. The Nfr2-ARE pathway induces transcription of antioxidant proteins and phase II detoxifying enzymes, which are important for protection of cells against ROS damage [23]. Thus this pathway may serve as a marker of oxidative stress damage. The three ERs family members, ERα, ERβ, and ERγ, play a novel functional role in the inhibitor of Nrf2 transcriptional activity. It is also the modulation of ERα and ERβ that may be useful as a therapeutic target in cancer chemoprevention studies or for the development of selective estrogen receptor modulators with a lower risk of causing cancer [2528].

In our continuous effort to search for novel anticancer agents from Mayan medicinal plants of the Yucatan peninsula, we recently isolated a novel compound from the medicinal plant Bonellia macrocarpa (Cavanilles) Ståhl and Källersjö. This new alkyl catechol, called bonediol, has been demonstrated to have interesting antiproliferative activities in vitro on cancer cell lines [29]. Accordingly, this study evaluated the antiproliferative properties of bonediol in various lines of prostate cancer and also explored its effect on the Shh signaling pathway, interactions with the Nrf2 antioxidant response element, and potential binding to estrogen receptors (ERα and ERβ).

2. Material and Methods

2.1. Isolation of Bonediol

Root bark of B. macrocarpa was collected from Telchac Puerto, Yucatan (Mexico). The plant material was identified and authenticated by taxonomists from the Department of Natural Resources of the Scientific Research Center of Yucatan (CICY). Specimens under the voucher number P. Simá 2979 were deposited at CICY’s U Najil Tikin Xiw herbarium. The obtaining and characterization of the compound were performed as previously described [29]. The pure compound was dissolved in DMSO and stored at −20°C.

2.2. Cell Culture

Cell lines of human prostate cancer adenocarcinoma (PC-3), a metastatic variant of PC-3 (PC-3M), hormone sensitive human prostate carcinoma (LNCaP), and one normal human cell line (HEK-293) were obtained from the American Type Culture Collection (ATCC). Shh Light II (JHU-68) and COS-1 cells lines were used to evaluate Shh and Nrf2-ARE pathways, respectively. The cells line PC-3 was propagated in F-12K medium (Gibco) and LNCaP in RPMI-1640 medium (Gibco). COS-1, HEK-293, and PC-3M cells lines were propagated in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco). Shh Light II cells were maintained in DMEM containing 4 mmol/L of L-glutamine adjusted with 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, supplemented with 0.4 mg/mL G-418 and 0.15 mg/mL zeocin (Invitrogen). All cell lines were cultured in sterile Costar T75 flasks containing fetal bovine serum (10% v/v), 100 U/mL penicillin G, and 100 mg/mL streptomycin at 37°C under a humid atmosphere containing 5% CO2.

2.3. Antiproliferative Activity

Cells were cultured in 96-well plates at a concentration of 5 × 104 cells per well; after being cultured for 24 h at 37°C in an atmosphere of 5% CO2 (95% humidity) cells were incubated with appropriate dilutions of the test compound for 48 h. The growth inhibition of the cell lines was evaluated by the sulforhodamine B method [30]. Results are expressed as the concentration of agent that reduces cell growth by 50% (IC50). Docetaxel was used as a positive control. All determinations were performed in triplicate. In addition, the degree of toxicity to normal cells was evaluated, by determining the selectivity index (SI) [31].

2.4. Assay of Inhibition from Hedgehog Pathway

Gli activity in the Shh Light II cell line was assayed after 48 h of treatment with bonediol compound in phenol red-free DMEM supplemented with 0.5% charcoal-stripped serum using the Dual Luciferase Reporter Assay System (Promega). Each experiment was performed at least thrice in duplicate. Mouse recombinant Shh was obtained from R&D Systems. Shh was dissolved in PBS with 0.1% bovine serum albumin. In each experiment, the controls and all treatments contained all vehicles used. All treatments were conducted in phenol red-free medium with charcoal-stripped serum [32]. Each experiment was performed at least thrice in duplicate.

2.5. Competitive Binding Assay

Proteins were synthesized using the TNT Coupled Reticulocyte Lysate System from Promega. In vitro transcription/translation products were treated individually with various concentrations of -17-β-E2 in the absence or presence of various doses of unlabeled competitors or unlabeled 17-β-E2 overnight at 4°C in order to achieve equilibrium binding. Bound and free ligand were separated by dextran-coated charcoal. Relative binding affinity (RBA) was determined by dividing the IC50 of the unlabeled 17-β-E2 by the IC50 of the unlabeled competitor.

2.6. Plasmid

The vectors containing Gal4-luciferase, the 4x mouse GST Ya subunit ARE (4 copies of the 41 bp GST Ya element) reporter, hemagglutinin (HA) tagged Nrf2, and the Nrf2 transactivation domain-Gal4 DNA binding domain fusion vector have been described previously [25, 28, 33]. phRG-TK control renilla luciferase vector was obtained from Promega.

2.7. Regulation of Antioxidant Response Element (Nrf2-ARE) Assay

The transcriptional activity of NF-E2 Related Factor 2 (Nrf2) on antioxidant response element (ARE) was monitored as previously described [25]. Briefly, COS-1 cells were seeded in 24-well plates in phenol red-free medium with 10% dextran-coated charcoal-stripped fetal bovine serum, for transient transfection with 150 ng 4x mouse GST Ya subunit ARE firefly luciferase reporter or Gal4-luciferase reporter, 10 ngphRGTK control renilla luciferase vector, and different expression vectors using plus and Lipofectamine reagents (Invitrogen, Carlsbad, CA). Constant transfected DNA amount was compensated by empty vector—pcDNA3.1(+)zeo (Invitrogen, Carlsbad, CA). After 12–16 h, transfected cells were then treated with bonediol or vehicle. After 24 h of incubation, cells were rinsed with PBS twice and lysed to measure the luciferase level using the Dual Luciferase assay kit (Promega, Madison, WI). Data were normalized to the cotransfected phRG-TK control renilla luciferase activity. All experiments were performed at least three times with duplicate samples per experiment.

2.8. Statistical Analysis

Graph Pad Prism 4 (Graph Pad Software, La Jolla, CA) was used to calculate values of which were considered significant in all cases. The IC50 were calculated using doses-response nonlinear fit curve. One-way analysis of variance (ANOVA) was used to assess significant differences among treated groups followed by Dunnett’s test.

3. Results

In order to explore the possible antiproliferative effect of the compound bonediol, a SRB assay was performed to determine whether this molecule was able to inhibit the growth of prostate cancer cells. A typical dose-response behavior was observed in all cell lines tested, with IC50 in the various cell lines tested ranging from 8.5 to 20.6 μM (Figure 1). Table 1 shows the median concentration that inhibited cell growth (IC50) and the selectivity index of bonediol towards all cell lines. Bonediol inhibited the growth of PC-3, LNCaP, and metastatic PC-3M cell lines with selectivity compared with Hek-293.

CompoundCell lines IC50μM (SI)

Bonediol33.218.1 (1.8)15.5 (2.1)13.3 (2.5)
Docetaxel1.100.23 (4.78)0.20 (5.50)0.08 (13.75)

Shh Light II cell, an NIH 3T3 cell line stably transfected with Gli1-dependent firefly luciferase and constitutive renilla luciferase reporters, was used to explore the ability of bonediol to inhibit Shh pathway activation. When we tested the model with various concentrations of bonediol (0.1, 0.5, 1, and 5 μM) no significant inhibition was observed compared with the control cyclopamine (data not shown).

We next analyzed the potential of bonediol to bind to estrogen receptors (ERα and ERβ) (Figure 2). Bonediol binds to both receptors in a dose-dependent manner; 2.5 μM and 2.1 μM displaced 50% of estradiol binding on ERα and ERβ, respectively.

As mentioned above, the activation of the Nrf2 signaling pathway governs the expression of ARE-driven genes. This pathway has been associated with induction of oxidative stress and in this study was used as a possible marker of oxidative damage from bonediol to the cells. Bonediol induces activation of Nrf2-ARE in transfected COS-1 cells at 1 μM (3.8-fold) and 5 μM (2.8-fold) (Figure 3). The results show that bonediol activates Nrf2-ARE signaling possibly through induction of oxidative stress.

4. Discussion

This study evaluated for the first time the activity of bonediol on binding to the estrogen receptors, inhibition of the Shh pathway, and activation of Nrf2-ARE signaling. Previous work demonstrated the potential antiproliferative effect of bonediol [29] and that this compound has no significant cytotoxic activity [34]. Furthermore, bonediol does not induce apoptosis at low doses [34]. We explored here the antiproliferative potential of bonediol against three prostate cancer lines (hormone sensitive (LNCaP), hormone insensitive (PC-3), and high metastatic hormone insensitive PC-3M) and the possible pharmacologic mechanisms. Bonediol has an antiproliferative effect in the three prostate cancer cell lines, indicating that this compound could have various pharmacologic mechanisms, both hormone-dependent and hormone-independent. Prostate cancer has been reported to have an altered Shh signaling as a pathway of importance in advanced growth and this pathway has recently been shown of interest in the search for new compounds that can inhibit cancer [32, 35]. However, bonediol did not demonstrate an inhibition of this signaling pathway to a concentration of 10 μM (data not shown). No further evaluations were performed at doses, since we observed damage to the cells without concomitant inhibition of Shh signaling. Interestingly, bonediol displaced 50% of estradiol on ERα and ERβ at concentrations of 2.1 and 2.5 μM, respectively. No studies on the estrogenic potential of alkyl catechols have been reported previously, but there are reports of related synthetic alkyl phenols compounds that have antiestrogenic effect [36]. Furthermore, some studies indicate that the main pharmacophore for recognition by the estrogen receptor is the presence of at least one phenolic alcohol and hydrophobic long chain [37, 38]. We do not know precisely how bonediol is binding to the ERs, but the presence of the two phenolic alcohols and long chain hydrophobic may be involved. The binding of the compound bonediol to the ERs does not indicate whether bonediol could be acting as an antagonist or as an agonist. Further studies are required to observe the way in which this compound could regulate either receptor. It is known that preferential ERβ activation has an antiproliferative effect in breast and prostate cells and is viewed as a protective balance against ERα activation, which is associated with proliferation [3941]. Bonediol may be regulating both ERα and ERβ, resulting in an antiproliferative effect on prostate cancer. Moreover, Nelles et al. [19] remarked the importance of development of new selective ER modulators with therapeutic potential.

Finally, we found that bonediol activates Nrf2-ARE signaling at a concentration of 1 μM (3.8-fold induction), which is indicative of oxidative stress and may be a mechanism of damage to the cell lines tested. However, another explanation for the activation of this pathway could be that some chemical compounds with antioxidant properties have the ability to be redox active and activate the Nrf2-ARE pathway [42]. In this context, some related alkyl phenols have shown antioxidant and prooxidant activity [43, 44]. Antioxidants from plants have been studied for the prevention of several cancer types, including prostate cancer, and it is currently believed that small doses of these compounds could have a beneficial effect by inducing the activation of antioxidant proteins and detoxifying enzymes, which would act against carcinogenic insults [23]. At a concentration of 5 μM bonediol had a slightly lower induction (2.8-fold), compared with the inductive effect at 1 μM (3.8-fold). This effect could be due to the compound exhibiting toxic effects in cell lines at the higher concentration.

In the course of our research we found that the compound bonediol is able to bind ERα and ERβ. This is the first report of the potential estrogenic activity of these compounds (alkyl catecohols), isolated from plants. Additionally, bonediol induces activation of Nrf2-ARE, possibly functioning as an antioxidant and generating oxidative stress.

Future studies aimed at elucidating how this compound binds to the estrogen receptors and the exact mechanism by which bonediol activates Nrf2-ARE will be beneficial to development of a potential new prostate cancer therapeutic.

5. Conclusion

In summary, we found that bonediol binds to both ERα and ERβ in the low micromolar range, has potential estrogenic activity, and can induce Nrf2 signaling. Furthermore, we propose that the compound bonediol may serve as a potential chemopreventive treatment with therapeutic potential against prostate cancer.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This project was made possible by Grant no. P50AT006273 from the National Center for Complementary & Alternative Medicine (NCCAM), the Office of Dietary Supplements (ODS), and the National Cancer Institute (NCI) and additionally a Grant no. CB 2010-01-156755 from CONACYT Mexico. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, ODS, NCI, or the National Institutes of Health. Rosa E. Moo-Puc received a postdoctoral Fellowship from CONACYT by the Project 2008/78749.


  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA—A Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at: Publisher Site | Google Scholar
  2. M. Bolla, T. M. de Reijke, G. van Tienhoven et al., “Duration of androgen suppression in the treatment of prostate cancer,” The New England Journal of Medicine, vol. 360, no. 24, pp. 2516–2527, 2009. View at: Publisher Site | Google Scholar
  3. L. Zhong, V. Pon, S. Srinivas et al., “Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis,” PLoS ONE, vol. 8, no. 5, Article ID e64275, 2013. View at: Publisher Site | Google Scholar
  4. American Cancer Society, Cancer Facts and Figures 2012, American Cancer Society, Atlanta, Ga, USA, 2012.
  5. J. Hoffman-Censits and M. Fu, “Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer?” Seminars in Oncology, vol. 40, no. 3, pp. 361–374, 2013. View at: Publisher Site | Google Scholar
  6. S. Terry, P. Maillé, H. Baaddi et al., “Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer,” Neoplasia, vol. 15, no. 7, pp. 761–772, 2013. View at: Publisher Site | Google Scholar
  7. L. Fan, C. V. Pepicelli, C. C. Dibble et al., “Hedgehog signaling promotes prostate xenograft tumor growth,” Endocrinology, vol. 145, no. 8, pp. 3961–3970, 2004. View at: Publisher Site | Google Scholar
  8. S. S. Karhadkar, G. S. Bova, N. Abdallah et al., “Hedgehog signalling in prostate regeneration, neoplasia and metastasis,” Nature, vol. 431, no. 7009, pp. 707–712, 2004. View at: Publisher Site | Google Scholar
  9. P. Sanchez, A. M. Hernández, B. Stecca et al., “Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 34, pp. 12561–12566, 2004. View at: Publisher Site | Google Scholar
  10. T. Sheng, C. Li, X. Zhang et al., “Activation of the hedgehog pathway in advanced prostate cancer,” Molecular Cancer, vol. 3, article 29, 2004. View at: Publisher Site | Google Scholar
  11. N. Okolowsky, P. A. Furth, and P. A. Hamel, “Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland,” Developmental Biology, vol. 391, no. 2, pp. 219–229, 2014. View at: Publisher Site | Google Scholar
  12. J. A. Taylor, C. A. Richter, R. L. Ruhlen, and F. S. Vom Saal, “Estrogenic environmental chemicals and drugs: mechanisms for effects on the developing male urogenital system,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 127, no. 1-2, pp. 83–95, 2011. View at: Publisher Site | Google Scholar
  13. K. Koga, M. Nakamura, H. Nakashima et al., “Novel link between estrogen receptor α and hedgehog pathway in breast cancer,” Anticancer Research, vol. 28, no. 2, pp. 731–739, 2008. View at: Google Scholar
  14. C. Kameda, H. Tanaka, A. Yamasaki et al., “The hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer,” Anticancer Research, vol. 29, no. 3, pp. 871–880, 2009. View at: Google Scholar
  15. C. Kameda, M. Nakamura, H. Tanaka et al., “Oestrogen receptor-α contributes to the regulation of the hedgehog signalling pathway in ERα-positive gastric cancer,” British Journal of Cancer, vol. 102, no. 4, pp. 738–747, 2010. View at: Publisher Site | Google Scholar
  16. M. Souzaki, M. Kubo, M. Kai et al., “Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer,” Cancer Science, vol. 102, no. 2, pp. 373–381, 2011. View at: Publisher Site | Google Scholar
  17. C. Xu, J. Li, Y. Lu, and Z. Jiang, “Estrogen receptor α and hedgehog signal pathway developmental biology of gastric adenocarcinoma,” Hepato-Gastroenterology, vol. 59, no. 116, pp. 1319–1322, 2012. View at: Publisher Site | Google Scholar
  18. A. Sĺusarz, G. A. Jackson, J. K. Day et al., “Aggressive prostate cancer is prevented in ERαKO mice and stimulated in ERβKO TRAMP mice,” Endocrinology, vol. 153, no. 9, pp. 4160–4170, 2012. View at: Publisher Site | Google Scholar
  19. J. L. Nelles, W.-Y. Hu, and G. S. Prins, “Estrogen action and prostate cancer,” Expert Review of Endocrinology & Metabolism, vol. 6, no. 3, pp. 437–451, 2011. View at: Publisher Site | Google Scholar
  20. J. Che, F.-Z. Zhang, C.-Q. Zhao, X.-D. Hu, and S.-J. Fan, “Cyclopamine is a novel hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells,” Oncology Letters, vol. 5, no. 4, pp. 1417–1421, 2013. View at: Publisher Site | Google Scholar
  21. R.-L. Dai, S.-Y. Zhu, Y.-P. Xia et al., “Sonic hedgehog protects cortical neurons against oxidative stress,” Neurochemical Research, vol. 36, no. 1, pp. 67–75, 2011. View at: Publisher Site | Google Scholar
  22. A. Paschos, R. Pandya, W. C. Duivenvoorden, and J. H. Pinthus, “Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics,” Prostate Cancer and Prostatic Diseases, vol. 16, pp. 217–225, 2013. View at: Publisher Site | Google Scholar
  23. X. Kou, M. Kirberger, Y. Yang, and N. Chen, “Natural products for cancer prevention associated with Nrf2–ARE pathway,” Food Science and Human Wellness, vol. 2, no. 1, pp. 22–28, 2013. View at: Publisher Site | Google Scholar
  24. Y. Zhang and G. B. Gordon, “A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway,” Molecular Cancer Therapeutics, vol. 3, no. 7, pp. 885–893, 2004. View at: Google Scholar
  25. P. J. Ansell, C. Espinosa-Nicholas, E. M. Curran et al., “In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens,” Endocrinology, vol. 145, no. 1, pp. 311–317, 2004. View at: Publisher Site | Google Scholar
  26. N. S. Shenouda, C. Zhou, J. D. Browning et al., “Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro,” Nutrition and Cancer, vol. 49, no. 2, pp. 200–208, 2004. View at: Publisher Site | Google Scholar
  27. P. J. Ansell, S.-C. Lo, L. G. Newton et al., “Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha,” Molecular and Cellular Endocrinology, vol. 243, no. 1-2, pp. 27–34, 2005. View at: Publisher Site | Google Scholar
  28. W. Zhou, S.-C. Lo, J.-H. Liu, M. Hannink, and D. B. Lubahn, “ERRβ: a potent inhibitor of Nrf2 transcriptional activity,” Molecular and Cellular Endocrinology, vol. 278, no. 1-2, pp. 52–62, 2007. View at: Publisher Site | Google Scholar
  29. E. Caamal-Fuentes, L. W. Torres-Tapia, R. Cedillo-Rivera, R. Moo-Puc, and S. R. Peraza-Sánchez, “Bonediol, a new alkyl catechol from Bonellia macrocarpa,” Phytochemistry Letters, vol. 4, no. 3, pp. 345–347, 2011. View at: Publisher Site | Google Scholar
  30. P. Skehan, R. Storeng, D. Scudiero et al., “New colorimetric cytotoxicity assay for anticancer-drug screening,” Journal of the National Cancer Institute, vol. 82, no. 13, pp. 1107–1112, 1990. View at: Publisher Site | Google Scholar
  31. G. Mena-Rejon, E. Caamal-Fuentes, Z. Cantillo-Ciau, R. Cedillo-Rivera, J. Flores-Guido, and R. Moo-Puc, “In vitro cytotoxic activity of nine plants used in Mayan traditional medicine,” Journal of Ethnopharmacology, vol. 121, no. 3, pp. 462–465, 2009. View at: Publisher Site | Google Scholar
  32. A. Ślusarz, N. S. Shenouda, M. S. Sakla et al., “Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer,” Cancer Research, vol. 70, no. 8, pp. 3382–3390, 2010. View at: Publisher Site | Google Scholar
  33. D. D. Zhang and M. Hannink, “Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress,” Molecular and Cellular Biology, vol. 23, no. 22, pp. 8137–8151, 2003. View at: Publisher Site | Google Scholar
  34. R. Moo-Puc, J. Chale-Dzul, and E. Caamal-Fuentes, “Bonellia albiflora: a mayan medicinal plant that induces apoptosis in cancer cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 823453, 8 pages, 2013. View at: Publisher Site | Google Scholar
  35. M. Lauth, Å. Bergström, T. Shimokawa, and R. Toftgård, “Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 20, pp. 8455–8460, 2007. View at: Publisher Site | Google Scholar
  36. S. J. Kwack, O. Kwon, H. S. Kim et al., “Comparative evaluation of alkylphenolic compounds on estrogenic activity in vitro and in vivo,” Journal of Toxicology and Environmental Health Part: A, vol. 65, no. 5-6, pp. 419–431, 2002. View at: Publisher Site | Google Scholar
  37. Y. Tabira, M. Nakai, D. Asai et al., “Structural requirements of para-alkylphenols to bind to estrogen receptor,” European Journal of Biochemistry, vol. 262, no. 1, pp. 240–245, 1999. View at: Publisher Site | Google Scholar
  38. B. J. Philips, P. J. Ansell, L. G. Newton et al., “Estrogen receptor-independent catechol estrogen binding activity: protein binding studies in wild-type, estrogen receptor-α KO, and aromatase KO mice tissues,” Biochemistry, vol. 43, no. 21, pp. 6698–6708, 2004. View at: Publisher Site | Google Scholar
  39. A. M. S. Covaleda, H. Van den Berg, J. Vervoort et al., “Influence of cellular ERα/ERβ ratio on the ERα-agonist induced proliferation of human T47D breast cancer cells,” Toxicological Sciences, vol. 105, no. 2, pp. 303–311, 2008. View at: Publisher Site | Google Scholar
  40. A. M. Sotoca, D. Ratman, P. van der Saag et al., “Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERα/ERβ ratio,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 112, no. 4-5, pp. 171–178, 2008. View at: Publisher Site | Google Scholar
  41. C. Williams, K. Edvardsson, S. A. Lewandowski, A. Ström, and J.-Å. Gustafsson, “A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells,” Oncogene, vol. 27, no. 7, pp. 1019–1032, 2008. View at: Publisher Site | Google Scholar
  42. S. Magesh, Y. Chen, and L. Hu, “Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents,” Medicinal Research Reviews, vol. 32, no. 4, pp. 687–726, 2012. View at: Publisher Site | Google Scholar
  43. M. Sumino, T. Sekine, N. Ruangrungsi, K. Igarashi, and F. Ikegami, “Ardisiphenols and other antioxidant principles from the fruits of Ardisia colorata,” Chemical and Pharmaceutical Bulletin, vol. 50, no. 11, pp. 1484–1487, 2002. View at: Publisher Site | Google Scholar
  44. S. Fujisawa, T. Atsumi, Y. Kadoma, and H. Sakagami, “Antioxidant and prooxidant action of eugenol-related compounds and their cytotoxicity,” Toxicology, vol. 177, no. 1, pp. 39–54, 2002. View at: Publisher Site | Google Scholar

Copyright © 2015 Rosa Moo-Puc et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.